Congress jumped into the health care game (again) by “complaining” that Gilead Sciences, Inc. (NASDAQ:GILD)’s hepatitis drug was priced too high. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.92% in last session and finished the day at $73.64. Traded volume was 19.50million shares in the last session and the average volume of the stock remained 13.29million shares. The beta of the stock remained 0.55. Gilead Sciences, Inc. (NASDAQ:GILD) insider ownership is 0.50%.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is 6.6% higher at $8.10, as traders digest rumors that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was willing to pay over $20 per share to buy the firm. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) rose 5.71 percent to $8.52 Tuesday on volume of 12.12million shares. The intra-day range of the stock was $8.02 to $8.55. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has a market capitalization of $1.59billion.

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2014 on Tuesday, April 29, 2014. During a conference call at 9 a.m. EDT on April 29, company executives will review financial information and will address inquiries from investors and analysts. Bristol-Myers Squibb Co (NYSE:BMY)’s stock on Apr 01, 2014 reported a decrease of -0.15% to the closing price of $51.87. Its fifty two weeks range is $39.18 -$57.49. The total market capitalization recorded $85.95billion. The overall volume in the last trading session was 7.33million shares. In its share capital, BMY has 1.66billion outstanding shares.

Natco Pharma Industries Ltd (ADR) (NYSE:TEVA) shares remain in focus after the US Supreme Court agreed to hear an appeal filed by Teva Pharmaceutical Industries Ltd in a patent fight over a drug for multiple sclerosis. Natco Pharma Industries Ltd (ADR) (NYSE:TEVA) stock declined 14% in trade yesterday. On Tuesday, shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) advanced 0.44% to close the day at $53.07. Company return on investment (ROI) is 4.90% and its monthly performance is recorded as 8.77%. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) quarterly revenue growth is 33.38%.